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The development of inhaled agonists selective for P,-adrenoceptors and high potency corticosteroids has 
improved the treatment of asthma. The delivery of the drugs to the site of action reduces the systemic 
exposure and hence reduces adverse systemic events. Together, these factors have resulted in improved 
toxicity : therapeutic ratios. Long-acting &agonists, such as salmeterol and formoterol, and high 
efficacy corticosteroids, such as fluticasone propionate and budesonide, now are available for clinical use. 
Because suboptimal treatment of asthma causes increased morbidity and mortality, and increased costs 
to society, these compounds are of particular value. Risk factors associated with fatal and near-fatal 
asthma have been identified, and it would appear that drug treatment by metered dose inhaler per se does 
not cause increased asthma fatality as an independent risk factor. 
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Mortality associated with asthma is considerably 
lower than for many other diseases. For a”given 
therapy, therefore, the acceptable level of side effects 
will be very low and the expected levels of efficacy 
very high. This makes asthma therapy a challenging 
area. 
P-agonists in the Treatment of Asthma 
The development of j?-adrenoceptor agonists, orig- 
inally based on the structures of adrenaline and 
noradrenaline, has resulted in compounds with 
specificity for /3,-adrenoceptors, such as salbutamol 
and terbutaline, and, more recently, the long-acting 
&agonists, salmeterol and formoterol (see Table 1). 
As formoterol is not yet available in the USA, this 
article focuses solely on salmeterol. After inhalation 
of a 5Opg dose, salmeterol produces peak broncho- 
dilation l-2 hours after dosing, equivalent to that 
obtained with 200 pug of salbutamol(1). Furthermore, 
salmeterol-induced bronchodilation lasts as long as 
12 hours, compared with approximately 4 hours for 
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salbutamol. This long duration of action results from 
repeated stimulation of the active site of the p2- 
adrenoceptor by the molecule’s polar ‘head’, while 
the long, nonpolar side-chain remains anchored to 
the hydrophobic exosite of the receptor (2). 
Because of the relatively slow onset and long 
duration of action, salmeterol is particularly useful 
for regular prophylactic treatment, rather than imme- 
diate symptomatic relief. In clinical trials, salmeterol 
has frequently been used as a replacement for other 
bronchodilators and added to existing regimens 
(including corticosteroids, sodium cromoglycate, 
nedocromil or ketotifen). In one study, salmeterol 
12.5, 50 and 100,ug twice daily was compared with 
placebo in 614 patients with mild to moderate asthma 
(3). In the patients receiving salmeterol, there was a 
dose-related increase in peak expiratory flow rate and 
dose-related reduction in diurnal variation in pulmo- 
nary function. Significant symptomatic improvement 
with salmeterol also was reported, with the 5Opg 
twice daily dose producing the optimal balance of 
efficacy and tolerability, based both on patients’ and 
physicians’ overall assessments. Moreover, in patients 
with moderate to severe asthma, salmeterol 50 or 
100 pug twice daily has been reported to cause dose- 
related improvements in peak expiratory flow rate, 
as well as reductions in the use of an additional 
bronchodilator as rescue medication (4). 
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TABLE 1. Selectivity of some P-adrenoceptor agonists. 
Potency* 
Airway smooth muscle Cardiac tissue 
Drug (P,-adrenoceptor) Cp, -adrenoceptor) Selectivity ratio 
Isoprenaline 1.0 1.0 1.0 
Fenoterol 0.6 0.005 120 
Formoterol 20.0 0.05 400 
Salbutamol 0.55 0.0004 1375 
Salmeterol 8.5 0.000 1 85,000 
*Potency expressed as relative to isoprenaline (=l.O) 
The long duration of action of salmeterol means 
that the drug is particularly useful in preventing 
nocturnal asthma symptoms. In a study of 17 patients 
with nocturnal asthma, salmeterol 50 or 100 pug twice 
daily was more effective than placebo in improving 
overnight peak expiratory flow rates and objective 
measurements of sleep; the 100 pug dose reduced 
significantly the requirement for rescue salbutamol 
during the night (5,6). Using a visual analogue scale 
to determine sleep quality, Ullman et al. (7) reported 
that patients receiving salmeterol 50,~~g twice daily, 
rated quality of sleep higher than those receiving 
salbutamol 200,~~g four times daily. In addition, 
several other placebo-controlled studies have demon- 
strated that awakenings, occurring as a result of 
nocturnal symptoms, are reduced by salmeterol50 or 
100,~~g twice daily (3,4,8). 
Comparative studies of salmeterol with other 
inhaled, short-acting, &adrenergic agonists, using 
large numbers of patients with varying asthma sever- 
ity, have shown salmeterol 50,~~g twice daily to be 
more effective than salbutamol 200,~~g four times 
daily or terbutaline 500 pg four times daily in increas- 
ing peak expiratory flow rates and in reducing day 
and night-time symptoms, diurnal variation and 
rescue salbutamol use. A meta-analysis of nine 
clinical trials comparing salmeterol with slow-release 
theophylline indicated significantly improved clinical 
responses in patients receiving salmeterol (11). 
Inhaled corticosteroids in the treatment of 
asthma 
Inhaled corticosteroids are used in various doses, 
depending upon the severity of asthma requiring 
treatment and on the delivery device being used. 
Because of differences in receptor affinity, lipophil- 
icity and delivery devices, it is not appropriate to 
assess potential toxic effects of these agents as dose 
equivalents. Hence, toxicity assessments for these 
drugs must be made at comparable levels of efficacy. 
The clinical efficacy of fluticasone propionate is twice 
that of beclomethasone dipropionate (BDP) or 
budesonide, both of which in turn are twice as 
effective as triamcinolone acetonide. However, the 
safety of these compounds at the various doses needs 
to be taken into account, since increased efficacy 
could also mean increased systemic activity and 
adverse events. 
One of the key benefits of using inhaled cortico- 
steroids is their ability to reduce the dosage of oral 
steroids (and hence reduce the systemic adverse 
events associated with these drugs) in those patients 
requiring them for effective asthma management. 
Noonan et al. (12) reported a study in which patients 
with severe asthma symptoms who were dependent 
on oral corticosteroids received either inhaled flutica- 
sone propionate, 750 or 1OOO~g twice daily, or 
placebo. Following 16 weeks of treatment, both fluti- 
casone propionate-treated groups had increased 
forced expiratory volume in 1 second (FEV,) values 
and peak expiratory flow rates (PEFR); the higher 
dose of fluticasone propionate caused significantly 
greater improvements than the lower dose. In 
addition, most patients receiving fluticasone propion- 
ate were able to either discontinue or significantly 
reduce the accompanying dose of oral steroids with- 
out worsening of their asthma (Table 2). Thus, night 
awakenings, rescue salbutamol use and patient-rated 
asthma symptoms were significantly reduced by 
fluticasone propionate, but there was no significant 
difference in these parameters between the two doses 
(Table 2). Thus, the additional improvement in 
symptom score for the higher dosage group compared 
with the lower one was modest in clinical terms. 
Chervinsky et al. (13) also found that fluticasone 
propionate, 25, 100 and 500,ug twice daily, was more 
effective than placebo in controlling mild to moderate 
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TABLE 2. Effect of fluticasone propionate (750 or 1000,~g twice daily) or placebo for 16 weeks on various outcome 
measures of patients with severe asthma. Data from Ref 12 
Variable 
Placebo 
Baseline Change 
FP 750,~g twice daily 
Baseline Change 
FP 1000 pg twice daily 
Baseline Change 
Morning PEF (L/min)a 
Evening PEF (L/min) 
Salbutamol use (puffs/day) 
Nocturnal awakening 
Prednisone dose (mg) 
Asthma symptom score 
332 - 15.0 307 40.1**+ 378 83.2**+ 
367 -24-l* 342 19*8* 422 54.1**+ 
9.2 0.91 8.9 - 3*04** 8.2 - 3.97** 
0.74 0.11 0.61 - 0.32** 0.68 - 0.63** 
10.2 1.6 9.5 - @j** 10.2 - 9.3**+ 
1.01 - 0.02 0.77 - 0.36 0.80 - 0.56** 
“Morning PEF was measured prior to any medication. 
*p-=0*05 versus baseline 
**p<O.O5 versus placebo 
+p<0.05 versus FP 75Opg twice daily. 
Abbreviations: FP: fluticasone propionate; PEF: peak expiratory flow. 
asthma, as assessed by FEV,, forced vital capacity which morning PEFR was the outcome measure and 
and PEF measurements. Over the 8-week treatment fluticasone propionate was administered at a 1:2 dose 
period, there were significant improvements in PEF ratio. Pooled data has shown mean morning PEF to 
rates and symptom scores, while night-time awaken- be somewhat higher with fluticasone propionate at 
ings and use of rescue salbutamol declined signifi- half the dose of budesonide (14). A meta-analysis 
cantly. Physician global assessments rated fluticasone comparing fluticasone propionate to BDP, showed a 
propionate as either effective or very effective in trend for greater efficacy of fluticasone propionate 
55-85% of patients; treatment was judged ineffective (15) but fluticasone caused minimally greater suppre- 
in 4- 17%. In addition, fluticasone propionate caused a sion of cortisol secretion (15). Some additional 
marked reduction in the number of severe episodes of studies have shown budesonide to have relatively less 
asthma and increased the probability of patients suppressive effect on serum cortisol than other 
remaining in the study (Fig. 1). inhaled corticosteroids (16). 
To obtain an overview of the efficacy : toxicity 
ratios of the various inhaled corticosteroids, meta- 
analyses have been performed of all trials of flutica- 
sone propionate, budesonide (14), and BDP (15) in 
It is important to remember in all cases that the 
alternative to inhaled corticosteroid therapy is oral 
corticosteroids, and these drugs will have more 
marked effects on adrenal suppression of cortisol 
secretion than any inhaled corticosteroid. 
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FIG. 1. Estimated probability of adult patients with 
mild-to-moderate asthma receiving either placebo, 
or fluticasone propionate (FP) 25, 100 or 5OOpg 
twice daily remaining in the study; *p<O.OOl vs 
placebo. (Reproduced with permission from 
Chervinsky et al., Ref 13). 
Risk factors associated with fatal asthma 
Spitzer et al. (17) suggested an apparent association 
between increased risk of death or near death from 
asthma and regular use of &-agonist bronchodilators. 
However, this study also showed that patients receiv- 
ing theophylline and inhaled corticosteroids had 
increased risk. This study was, however, subject to 
confounding by failure to analyse severity of illness. 
Subsequent studies from the same population of 
patients showed no correlation between &-agonist 
MD1 use and serious adverse events in asthmatic 
patients (18). 
Asthma therapy usually focuses on improvements 
in clinical condition and patient’s quality of life. 
However, a study by Marquette et al. (19) examined 
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the long-term prognosis of near-fatal asthma. They 
reported that a subset of patients 40 years old, 
who had previously been intubated because of 
life-threatening asthma, had a mortality rate of 
approximately 40% by the end of 5 years. Potential 
risk factors associated with fatal asthma (sudden 
onset fatal asthma or fatal asthma syndrome) include 
prior frequent hospitalisation, especially if previously 
intubated, and steroid dependency. The incidence of 
fatal asthma varies considerably among countries. 
The reasons for this cannot be easily identified, but it 
is extremely unlikely to be drug-related as the same 
drugs are used in most developed countries. In the 
USA, socio-economic factors have been shown to be 
important risk factors. Over a IO-year period, 
between 1978 and 1987, the incidence of fatal asthma 
was 3-times greater and increasing among black com- 
pared with white Americans, where it decreased 
slightly (20). Changes in mortality rate may not be 
related to drug treatment, lack of drug treatment, or 
a change in disease. For example, in Chicago, the 
increase in deaths occurring as a result of tuberculosis 
increased eight-fold, while during the same period, 
asthma-related deaths increased three-fold. 
Summary 
There is strong emphasis in the new treatment guide- 
lines issued by The Expert Panel of NHLBI that 
asthma should be treated as a disease of stages. 
Treatment should not only be directed to a particular 
stage, but should initially be focused on the highest 
level for that stage to gain control of the disease as 
quickly as possible. Long-acting &Agonists and 
inhaled corticosteroids, either alone or in combina- 
tion, significantly improve the clinical signs and 
symptoms of asthma. Administration of &- 
adrenergic agonists by inhalation results in no signifi- 
cant loss in their effectiveness, but a significant 
decrease in their systemic activity, resulting in 
improved efficacy : safety ratios. Systemic adverse 
events are usually observed only at very high inhaled 
dosages, and even at these doses, drug therapy does 
not appear to be related to asthma mortality. 
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